Brief: Incyte Announces European Commission Approval Of Minjuvi (Tafasitamab)
17/12/2025 20:26
Dec 17 (Reuters) - Incyte Corp INCY.O: INCYTE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF MINJUVI® (TAFASITAMAB) FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA Source text: ID:nBw10m5nGa Further company coverage: INCY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler